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confirms that the clinical outcome for patients followed up by community optometrists is similar to that for those who remained in the conventional hospital eye clinic. That should not surprise us because we know from many years of experience sharing patient care with optometrists, orthoptists, and nurse specialists, that our colleagues in these professions can be relied on to work with precision and integrity. The General Medical Council distinguishes delegation from referral. 2 Shared care schemes 3 are examples of delegation where the medical practitioner, in this case the ophthalmologist, remains responsible for the overall management of the patient and has a duty to ensure that the optometrist is suitably trained and qualified for the task. The separate process of referral to an optometrist will also be appropriate for some patients in whom a possible but low risk of glaucoma has been identified. They are referred to the community optometrist for the usual regular eye examination with the request that they be sent back to the ophthalmologist if the findings indicate an increasing risk. Here, it is the optometrist who assumes professional responsibility. Therefore when setting up shared care schemes it is necessary to avoid overloading the system with patients who should be referred (discharged) to the optometrist. Even when patients are properly included in shared care schemes they should be reviewed periodically and discharged to the care of an optometrist if, after a period of supervision, the risk of glaucoma is judged to be reduced.
The Bristol study uses a commendably simple test of field of vision which is rapid and reliable, without the spurious hyperaccuracy of more complex testing stratagems. This is one example of the strict discipline of the study and it minimises inaccuracies which might be caused by the use of diVerent field testing equipment or programmes. In other ways the problems of communication and standardisation have been closely controlled, but this may not always be possible and could aVect reliability when shared care is developed elsewhere. It is surprising to note that 55% of the community patients were sent back to hospital at least once in the relatively short (for glaucoma) follow up period of 2 years. This seems a high figure for such a carefully specified scheme and it may limit the eYciency and viability of the system.
The great source of disappointment in the experience of the Bristol group is that the cost analysis shows the community based scheme to be so much more expensive than the hospital clinic that it is likely to overwhelm the balancing advantage of improved geographic access. If lack of hospital capacity is a problem then expanding that capacity would be more cost eVective and, in any case, the stable glaucoma patients are likely to require follow up visits at infrequent intervals of between 6 months and 1 year. It is therefore likely that the cost will be the critical factor in deciding whether shared care for glaucoma in the community will be worthwhile. Calculating the true cost will be complex and must assess five elements: the cost of each examination in terms of staV, equipment, and administrative overheads; the cost of timely communication between the professionals who share the care; the cost of additional examinations which take place because there has been uncertainty about the significance of a resultuncertainty may be more likely to occur if a practitioner sees few patients and consequently has less extensive experience; the opportunity costs of losing the ability to deploy professional skills elsewhere; and the cost of unnecessary examination of patients whose risk of sight threatening disease is so low that they should be discharged. If sufficient care is taken to supervise the shared care schemes in the community, there is no doubt they can be safe and eVective but it is likely that they will not represent the most eYcient use of resources, except in areas where travel to the hospital clinic is especially diYcult. Selective ganglion cell death in glaucoma
The primate visual system is designed to provide maximum performance under a variety of conditions. Much of the enhanced sensitivity of the rod system comes from post-receptor neuronal organisation that pools impulses from thousands of receptors. In the retinal periphery multiple rods converge onto a single ganglion cell resulting in poor acuity but high sensitivity. At the fovea a one to one relation between cone and ganglion cell produces fine discrimination, colour perception and, by fusing the images of both eyes, binocular vision.
The "receptive field" for an individual ganglion cell is determined by the spatial arrangement of the connecting receptor fibres. These are designed to enhance perception of the stimulus and is achieved by an antagonistic arrangement of a concentric centre surround response where the surround is opposite in polarity to the centre. 1 Ganglion cells have been subdivided according to their temporal response properties. Primate ganglion cells have been divided into tonic and phasic types. 2 Phasic cells respond transiently to changes in stimulus, while tonic ones provide a more sustained response. Phasic ganglion cells have both rod and cone input, make up about 10% of the total, and have large overlapping receptive fields. They subserve motion and contrast function and project via large diameter fibres to the magnocellular layers of the lateral geniculate body. Tonic ganglion cells by contrast are small, with small receptive fields and slower conducting axons. They comprise 80% of all ganglion cells with maximum representation for the foveal cones. They subserve colour and discriminatory function and project to the parvocellular layers of the lateral geniculate body. 3 The axon size would appear to diVer according to the cone wavelength perceived, with short wavelength cones having the largest diameter fibres. 4 These cells connecting to the magnocellular and parvocellular layers of the lateral geniculate body are also known as parasol cells (feeding to the magno system, and therefore "M" cells) and midget cells (feeding to the parvo system, "P" cells).
The idea of separate visual function based on diVerent receptors and diVerent post-receptor organisation has led to the concept of "parallel visual processing". This concept has proved useful for identifying diVerent aspects of visual loss in ocular disease.
The search for specific tests which made use of this psychophysical separation was greatly stimulated by the discovery that glaucoma was associated with selective ganglion cell death. Histological examination of eye with "early glaucoma" revealed that substantial numbers of ganglion cells were lost before defects appeared with white on white perimetry. 5 In the experimental monkey model large ganglion cells were found to be more vulnerable, although the magnitude of this selective loss varied. 6 Human necropsy material showed relatively greater loss of magnocellular cells in glaucoma. 7 These pieces of evidence pointing to selective cell death have led to the development of tests of large fibre ganglion cells including contrast sensitivity, 8 motion detection, 9 and, perhaps, frequency doubling. 10 Recently, the theory that selective cell death first aVects large fibre ganglion cells has been questioned. Sample and associates reported on the results of testing glaucoma patients with short wavelength perimetry and motion automated perimetry, and found that both tests successfully diagnosed glaucomatous damage. 11 They suggested that in glaucoma the damage that occurs may aVect either the magnocellular or parvocellular system, or that there may be individual diVerences between eyes that decide which system is damaged first. The numeric diVerence between the two types of ganglion cells could mean a disproportionate eVect on visual function if equal numbers of M and P cells were lost in disease. Willis and Anderson noted that the age related rate of decline was faster in the glaucomatous eye than the normal eye. 12 Morgan has suggested that the appearance of diVerential cell death could be an artefact due to postmortem shrinkage producing the impression of large cell loss.
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In the March issue of the BJO, Morgan and coworkers contributed further to this debate.
14 They induced ocular hypertension in six primate eyes and then examined the retinal ganglion cell populations after retrograde labelling with horseradish peroxidase. They did not find a significant reduction in the proportion of parasol to midget cells. They did find an overall reduction in mean size for both the surviving M and P cells suggesting cell compromise before cell death. They pointed out that the use of a tracer to study the ganglion cell changes induced by ocular hypertension was not subject to the potential for artefact inherent in the methodology of earlier studies. They noted that another similar primate study 15 also found a reduction in cell size before cell loss (although the exact significance of this finding was open to interpretation).
Where does this debate leave the clinician who is looking to detect early glaucomatous visual loss? Selective cell death may still occur in early glaucoma, although alternative explanations are possible. However, this doubt as to mechanism does not remove the validity of selective psychophysical testing. Whether the tests target the magno or the parvo system they are still likely to provide earlier diagnosis than white on white perimetry and as such should continue to be introduced into clinical practice.
Morgan and co-workers are to be thanked for reminding us that in biological systems all is rarely black and white, and that even certainties in medicine are worth reexamination. Their work has caused us to rethink the process by which ganglion cells are damaged in hypertensive eyes. In addition, by identifying premortem changes in the ganglion cell size that suggested compromise, they may have also provided a marker for worthwhile studies on neuroprotection in the future. What is Sorsby's fundus dystrophy?
The past decade has seen a resurgence of interest in the molecular defects underlying macular dystrophies. Firstly, this is because these diseases are important causes of incurable blindness and, secondly, the molecular defects highlighted by these studies may be relevant to the much commoner disease, age related macular degeneration (AMD). In this issue, Assink et al (p 682) have undertaken a molecular genetic study of one of these macular dystrophies: Sorsby's fundus dystrophy (SFD), an important addition to the literature, which also raises new questions.
The scientific literature describes SFD as a fully penetrant, autosomal dominant, retinal disease first described by Sorsby in 1949. 1 Clinically, early, midperipheral, drusen 2 and colour vision deficits are found. 3 Some patients complain of night blindness. 4 Most commonly, the presenting symptom is sudden acuity loss, manifest in the third to fourth decades of life, due to untreatable submacular neovascularisation. Parametric linkage analysis originally localised the SFD gene to chromosome 22q13-qter 6 between marker loci D22S273 and D22S281. Subsequently, five diVerent missense mutations 7 and a splice site mutation 7 have been identified in TIMP3 (tissue inhibitor of metalloproteinases 3). In the British Isles, to date, all SFD families carry the same Ser181Cys TIMP3 mutation and it has been suggested that this all relates to one single founder.
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TIMP3 encodes a retinal pigment epithelium expressed member of a group of zinc binding endopeptidases involved in retinal extracellular matrix remodelling, particularly in Bruch's membrane. 9 Assink et al describe a large family with autosomal dominant maculopathy, the earliest features being drusen and "pisciform" lesions in the fourth decade of life. These are later complicated by disciform lesions that progress to chorioretinal atrophy. A key question is, does this truly represent the SFD phenotype? Pisciform lesions are not a feature normally associated with Sorsby's fundus dystrophy. Also, delayed choroidal filling on fluorescein angiography is thought to be a cardinal SFD finding but is not seen in this study family. 2 Other maculopathies are known to lead to drusen and subretinal neovascularisation in this age group. For instance, the study family may represent an example of dominant drusen? Or, alternatively, does the study describe a new phenotype? Is it important that a family diagnosed as expressing SFD has exactly the symptoms and signs itemised in the literature or is it suYcient that they express the cardinal features as suggested in this study? Should SFD be confined to haemorrhagic maculopathies with proved TIMP3 mutation?
Have Assink et al truly excluded an association between TIMP3 and the phenotype expressed in their study? To completely exclude TIMP3 not only must coding sequence be screened but also the promoter and enhancer sequences that control TIMP3 expression. The authors have almost but not entirely done this. Most pertinent here are the enhancer sequences which can be found quite distant from the relevant gene. These sequences could conceivably lie within the D2S275 and D2S274 linked region and be composed of an as yet unknown sequence; mutation therefore becoming impossible to exclude.
Sorsby's fundus dystrophy, both clinically and histopathologically, shares some similarities with AMD. It is appropriate, therefore, that TIMP3 coding sequence be screened in cohorts expressing this much more frequent cause of blindness in the developed world. No TIMP3 mutation, however, has yet been associated with AMD. Genes associated with other macular dystrophies have also undergone mutation screen in AMD (Table 1) . No positive association has yet been identified except initially in the case of ABCA4. 10 Recent work, however, has cast doubt on a link between ABCA4 mutation and AMD. The initial, positive, association has not been reproduced in other studies and ABCA4 has proved to be such a polymorphic gene that large numbers of base changes in unaVected control groups have cast doubt on the significance of ABCA4 base changes in AMD patients. Despite this, screening genes causing rare macular dystrophies for mutation in AMD is still a valid undertaking. Mutation of the glucagon gene in rare families expressing early onset, autosomal dominant, diabetes mellitus leads to a significant association between this gene and diabetes mellitus as more commonly seen as a polygenic complex trait.
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Regardless of whether the study family truly has SFD or whether the work will prove helpful in identifying AMD genes, the work presented by Assink et al is an important contribution to the ocular genetics literature. Retinal dystrophies are proving to be among the most genetically heterogeneous conditions known, with dozens of genes now associated with inherited disease of the retina and with more to come. This is beginning to stimulate interest in unravelling of the molecular steps involved in these diseases. It is possible that as we more fully understand the complexity of the molecular consequences of mutation, new ideas will emerge of how to modify progression of disease in a way that may prove more practical than "conventional" gene therapy protocols that treat the primary gene deficit.
KEVIN GREGORY-EVANS Western Eye Hospital, Imperial College School of Medicine, London NW1 5YE k.gregory-evans@ic.ac.uk
